Skip to main content
. Author manuscript; available in PMC: 2014 Mar 1.
Published in final edited form as: Gene Ther. 2013 Jul 11;20(12):10.1038/gt.2013.40. doi: 10.1038/gt.2013.40

Figure 5.

Figure 5

(a) Ad5-yCD/mutTKSR39rep-mIL12 anti-tumor activity in subcutaneous model. C57BL/6 male mice bearing subcutaneous TRAMP-C2 tumors (mean 120 mm3) were injected intratumorally with saline, Ad5-yCD/mutTKSR39rep (5 × 108 PFU) or Ad5-yCD/mutTKSR39rep-mIL12 (5 × 108 PFU) on days 0, 4 and 7 (arrowheads). Prodrug-treated groups were administered 5-FC + GCV for 2 weeks beginning on day 11 (hatched bar). Animals were killed when tumors reached 2,000 mm3 or when animals became moribund (defined as survival). The study was terminated on day 90. (b) Ad5-yCD/mutTKSR39rep-mIL12 antitumor activity in orthotopic model. C57BL/6 male mice bearing intraprostatic TRAMP-C2 tumors were injected intratumorally with saline, Ad5-yCD/mutTKSR39rep (5 × 108 PFU) or Ad5-yCD/mutTKSR39rep-IL12 (5 × 108 PFU) on day 0 (arrowhead). Prodrug-treated groups were administered 5-FC + GCV for 2 weeks beginning on day 2 (hatched bar). Animals were followed until death or killed when they became moribund (defined as survival). The study was terminated on day 60.